This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Calhoun, D. A. Articles by Carey, R. M. Search for Related Content PubMed PubMed Citation Articles by Calhoun, D. A. Articles by Carey, R. M. Related Collections Obesity Compliance/Adherence Type 2 diabetes Clinical Studies AHA Statements and Guidelines

(Circulation. 2008;117:e510-e526.)
© 2008 American Heart Association, Inc.

AHA Scientific Statement

Resistant Hypertension: Diagnosis, Evaluation, and Treatment

A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research

David A. Calhoun, MD, FAHA, Chair; Daniel Jones, MD, FAHA; Stephen Textor, MD, FAHA; David C. Goff, MD, FAHA; Timothy P. Murphy, MD, FAHA; Robert D. Toto, MD, FAHA; Anthony White, PhD; William C. Cushman, MD, FAHA; William White, MD; Domenic Sica, MD, FAHA; Keith Ferdinand, MD; Thomas D. Giles, MD; Bonita Falkner, MD, FAHA; Robert M. Carey, MD, MACP, FAHA

Resistant hypertension is a common clinical problem faced by both primary care clinicians and specialists. While the exact prevalence of resistant hypertension is unknown, clinical trials suggest that it is not rare, involving perhaps 20% to 30% of study participants. As older age and obesity are 2 of the strongest risk factors for uncontrolled hypertension, the incidence of resistant hypertension will likely increase as the population becomes more elderly and heavier. The prognosis of resistant hypertension is unknown, but cardiovascular risk is undoubtedly increased as patients often have a history of long-standing, severe hypertension complicated by multiple other cardiovascular risk factors such as obesity, sleep apnea, diabetes, and chronic kidney disease. The diagnosis of resistant hypertension requires use of good blood pressure technique to confirm persistently elevated blood pressure levels. Pseudoresistance, including lack of blood pressure control secondary to poor medication adherence or white coat hypertension, must be excluded. Resistant hypertension is almost always multifactorial in etiology. Successful treatment requires identification and reversal of lifestyle factors contributing to treatment resistance; diagnosis and appropriate treatment of secondary causes of hypertension; and use of effective multidrug regimens. As a subgroup, patients with resistant hypertension have not been widely studied. Observational assessments have allowed for identification of demographic and lifestyle characteristics associated with resistant hypertension, and the role of secondary causes of hypertension in promoting treatment resistance is well documented; however, identification of broader mechanisms of treatment resistance is lacking. In particular, attempts to elucidate potential genetic causes of resistant hypertension have been limited. Recommendations for the pharmacological treatment of resistant hypertension remain largely empiric due to the lack of systematic assessments of 3 or 4 drug combinations. Studies of resistant hypertension are limited by the high cardiovascular risk of patients within this subgroup, which generally precludes safe withdrawal of medications; the presence of multiple disease processes (eg, sleep apnea, diabetes, chronic kidney disease, atherosclerotic disease) and their associated medical therapies, which confound interpretation of study results; and the difficulty in enrolling large numbers of study participants. Expanding our understanding of the causes of resistant hypertension and thereby potentially allowing for more effective prevention and/or treatment will be essential to improve the long-term clinical management of this disorder.

Key Words: AHA Scientific Statements • hypertension • blood pressure

This article has been cited by other articles:

				E. S. Muxfeldt, C. R. L. Cardoso, and G. F. Salles Prognostic Value of Nocturnal Blood Pressure Reduction in Resistant Hypertension Arch Intern Med, May 11, 2009; 169(9): 874 - 880. [Abstract] [Full Text] [PDF]

				P. W. Sanders Dietary Salt Intake, Salt Sensitivity, and Cardiovascular Health Hypertension, March 1, 2009; 53(3): 442 - 445. [Full Text] [PDF]

				A. C. Tonelli de Oliveira, D. Martinez, L. F. T. Vasconcelos, S. Cadaval Goncalves, M. do Carmo Lenz, S. Costa Fuchs, M. Gus, E. Oliveira de Abreu-Silva, L. Beltrami Moreira, and F. Danni Fuchs Diagnosis of Obstructive Sleep Apnea Syndrome and Its Outcomes With Home Portable Monitoring Chest, February 1, 2009; 135(2): 330 - 336. [Abstract] [Full Text] [PDF]

				J. A. Phipps, A. C. Clermont, S. Sinha, T. J. Chilcote, S.-E. Bursell, and E. P. Feener Plasma Kallikrein Mediates Angiotensin II Type 1 Receptor-Stimulated Retinal Vascular Permeability Hypertension, February 1, 2009; 53(2): 175 - 181. [Abstract] [Full Text] [PDF]

				P. A. Sarafidis and G. L. Bakris Resistant Hypertension An Overview of Evaluation and Treatment. J. Am. Coll. Cardiol., November 25, 2008; 52(22): 1749 - 1757. [Abstract] [Full Text] [PDF]

				G. F. Salles, C. R. L. Cardoso, and E. S. Muxfeldt Prognostic Influence of Office and Ambulatory Blood Pressures in Resistant Hypertension Arch Intern Med, November 24, 2008; 168(21): 2340 - 2346. [Abstract] [Full Text] [PDF]